{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:09:00Z","timestamp":1792483740358,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ad.2024.08.014","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:31:55Z","timestamp":1740709915000},"page":"675-683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study"],"prefix":"10.1016","volume":"116","author":[{"given":"J.","family":"Ceravalls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Gim\u00e9nez-Arnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Exp\u00f3sito-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fern\u00e1ndez Chico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lara Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bielsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rib\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mascar\u00f3-Hereza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bonfill-Ort\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Spertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baliu-Piqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mel\u00e9-Ninot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.08.014_bib0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.ad.2024.08.014_bib0125","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.ad.2024.08.014_bib0130","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jdv.15350","article-title":"Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients","volume":"33","author":"Marzano","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.08.014_bib0135","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jaip.2020.03.022","article-title":"Omalizumab re-treatment and step-up in patients with chronic spontaneous urticaria: OPTIMA trial","volume":"8","author":"Sussman","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ad.2024.08.014_bib0140","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ad.2018.07.005","article-title":"Algorithm for treatment of chronic spontaneous urticaria with omalizumab","volume":"109","author":"Spertino","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2024.08.014_bib0145","doi-asserted-by":"crossref","first-page":"100501","DOI":"10.1016\/j.waojou.2020.100501","article-title":"Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both","volume":"14","author":"Chen","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.ad.2024.08.014_bib0150","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1016\/j.jaip.2020.06.056","article-title":"Effective omalizumab interval prolongation in the treatment of chronic urticaria","volume":"8","author":"Alizadeh Aghdam","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ad.2024.08.014_bib0155","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaip.2018.04.003","article-title":"Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis","volume":"6","author":"Ferrer","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ad.2024.08.014_bib0160","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1016\/j.jaip.2023.07.030","article-title":"Age and fast initial response predict omalizumab retreatment in chronic urticaria","volume":"11","author":"Meertens","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ad.2024.08.014_bib0165","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.jaci.2017.08.007","article-title":"Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria","volume":"140","author":"Ertas","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2024.08.014_bib0170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.anai.2020.04.026","article-title":"Addition of omalizumab to antihistamine treatment in chronic urticaria: a real-world study in China","volume":"125","author":"Chen","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.ad.2024.08.014_bib0175","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2217\/imt-2020-0088","article-title":"Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment","volume":"12","author":"Grieco","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ad.2024.08.014_bib0180","doi-asserted-by":"crossref","first-page":"e15248","DOI":"10.1111\/dth.15248","article-title":"Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria","volume":"35","author":"Foti","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2024.08.014_bib0185","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000529250","article-title":"Analysis of the efficacy and recurrence of omalizumab use in the treatment of chronic spontaneous urticaria and chronic inducible urticaria","volume":"184","author":"Yang","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.ad.2024.08.014_bib0190","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.abd.2022.06.003","article-title":"Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience","volume":"98","author":"Akda\u015f","year":"2023","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ad.2024.08.014_bib0195","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.jaci.2018.07.032","article-title":"Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria","volume":"142","author":"Niemeyer-van der Kolk","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2024.08.014_bib0200","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ajd.13656","article-title":"Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: real-life data","volume":"62","author":"Salman","year":"2021","journal-title":"Aust J Dermatol"},{"key":"10.1016\/j.ad.2024.08.014_bib0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/ejd.2024.4600","article-title":"Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review","volume":"34","author":"Gimenez-Arnau","year":"2024","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2024.08.014_bib0210","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211065870","article-title":"Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria","volume":"35","author":"Sirufo","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ad.2024.08.014_bib0215","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjd.16379","article-title":"Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria","volume":"179","author":"Curto-Barredo","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.08.014_bib0220","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaip.2018.06.011","article-title":"The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment","volume":"7","author":"Matucci","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ad.2024.08.014_bib0225","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/all.13352","article-title":"C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria","volume":"73","author":"Kolkhir","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.ad.2024.08.014_bib0230","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jaip.2023.01.022","article-title":"Omalizumab in Chronic Spontaneous Urticaria (CSU): real-life experience in dose\/interval adjustments and treatment discontinuation","volume":"1","author":"Br\u00e1s","year":"2023","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T08:02:04Z","timestamp":1753084924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0001731025001097"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.08.014","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}